The Indian healthcare sector is witnessing a localised “gold rush” as specialty hospital chains race to tap the primary markets. The latest contender to join the fray is Maxivision Super Specialty Eye Hospitals. According to a Bloomberg report, the Hyderabad-based chain has initiated discussions with investment bankers to structure an IPO that could hit the floor as early as late 2026. Notably, the company is backed by private equity firm Quadria Capital.

Maxivision is led by veteran healthcare entrepreneur Dr. G.S.K. Velu. The company is currently in the midst of an aggressive expansion phase. With a war chest of INR 1,300 crore raised from Quadria in 2023, the firm is pivoting from its Southern stronghold into Gujarat, Maharashtra, and Madhya Pradesh via a unique “Doctor-Entrepreneur” partnership model.

Past Performance of Hospital Sector IPOs: High Stakes, Higher Rewards

According to data compiled by IPO Central, the hospital sector has presented a “mixed bag” for investors at the starting line, but a goldmine for those with patience. Over the last eight years, the sector has seen 10 pure hospital play IPOs, raising a cumulative INR 13,189.09 crore.

The listing day performance has been a coin flip—5 IPOs listed in the green and 5 in the red—with an average listing day return of 7.15%. However, the real story lies in the post-listing momentum. Out of these 10 debutants, 6 have delivered multifold returns, proving that hospital stocks are long-term compounding machines rather than short-term listing gain plays.

Read Also: ASG Eye Hospitals Lines Up 2026 IPO

Maxivision vs. Dr Agarwal’s

For Maxivision Eye Hospital IPO, the most relevant benchmark is Dr. Agarwal’s Health Care. As a pure-play eye care peer, its performance serves as a direct indicator of investor sentiment for specialized ophthalmology vs. multi-specialty giants.

While multi-specialty players like KIMS (303% returns) and Global Health/Medanta (217% returns) have seen explosive growth, Dr. Agarwal’s has maintained a more conservative trajectory. Despite its massive brand equity, the stock has delivered a modest 8.46% return from its IPO price, underperforming the broader hospital “multibaggers.” Maxivision will need to convince D-Street that its aggressive expansion and “hub-and-spoke” efficiency can deliver the high-octane growth that the market currently rewards.

Hospital Sector IPO Performance (Last 8 Years)

CRISIL’s Report on Maxivision Eye Hospitals

Maxivision Eye Hospital’s internal financials suggest it is ready for the rigours of a public listing. According to a CRISIL report in 2025, its rating is reaffirmed to ‘Crisil BBB+/Stable’ rating, highlighting:

• Revenue Trajectory: Expected to cross INR 500 crore in FY26 and targeting INR 800 crore by FY27.
• Strong Solvency: Adjusted net worth improved to over INR 600 crore following the PE infusion.
• Margin Resilience: Maintaining healthy operating margins above 15% despite the costs associated with greenfield and brownfield acquisitions.

Bottom Line

Maxivision Eye Hospitals enters a market that is clearly “pro-hospital” but increasingly selective. While the average listing gain of 7.15% is modest, the massive wealth destruction seen in GPT Healthcare (-25%) vs. the wealth creation in KIMS (303%) shows that execution is everything.

Maxivision’s challenge will be to differentiate itself from the relatively slow start of Dr. Agarwal’s. If it can demonstrate that its partnership model in Maharashtra and Gujarat can scale faster than traditional organic growth, it may well join the elite “multifold” club of Indian hospital stocks.

Rajat Bhati has a strong technical background and 5 years of experience in the stock market. He focuses on equity research, technical analysis, IPO valuations, and risk management, helping investors make clearer, data-backed decisions. Today, he works full-time to educate people about the opportunities in IPO market.